Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.

NCT04329611 is registered in ClinicalTrials.gov with Dr. Michael Hill as lead sponsor.

NCT NCT04329611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04329611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.
Lead sponsor
Dr. Michael Hill
Phase
Phase 3
Overall status
Terminated
Start date
April 13, 2020
Completion date
July 20, 2020
Enrollment
148 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19